David A. Siegel Verona Pharma PLC Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$16.3 - $22.09 $3.92 Million - $5.31 Million
-240,483 Reduced 83.42%
47,800 $779,000
Q2 2023

Aug 14, 2023
BUY
$19.41 - $23.43 $494,625 - $597,066
25,483 Added 9.7%
288,283 $6.09 Million
Q1 2023

May 15, 2023
BUY
$18.06 - $25.27 $780,192 - $1.09 Million
43,200 Added 19.67%
262,800 $5.28 Million
Q4 2022

Feb 14, 2023
BUY
$9.84 - $26.13 $651,408 - $1.73 Million
66,200 Added 43.16%
219,600 $5.74 Million
Q3 2022

Nov 14, 2022
BUY
$4.14 - $13.59 $635,076 - $2.08 Million
153,400 New
153,400 $1.57 Million

Others Institutions Holding VRNA

# of Institutions
166
Shares Held
68.7M
Call Options Held
704K
Put Options Held
685K
View Full List

About Verona Pharma plc

VRNA Quotes by TradingView
  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.17B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email